M. Lebwohl, “Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials”, J of Skin, vol. 8, no. 1, p. s305, Jan. 2024.